19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
21:31 , May 10, 2018 |  BC Innovations  |  Emerging Company Profile

Abac’s precision platform

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics. The company’s PasNas platform uses phenotypic and...
19:34 , May 3, 2018 |  BC Innovations  |  Emerging Company Profile

Come together

Aelin Therapeutics N.V. is developing first-in-class synthetic peptides that could treat antibiotic-resistant Gram-negative infections by inducing toxic protein aggregation within bacterial cells. By harnessing a novel mechanism of action that disrupts proteostasis, Aelin could circumvent...
21:13 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Boehringer increases investment fund, expands focus

Boehringer Ingelheim GmbH (Ingelheim, Germany) said on Jan. 3 it added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment...
21:47 , Jan 3, 2018 |  BC Extra  |  Financial News

Boehringer Ingelheim enlarges investment fund

Boehringer Ingelheim GmbH (Ingelheim, Germany) added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment focus to include regenerative medicine,...
16:23 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Aelin raises €27M in series A

On Dec. 11, Aelin Therapeutics N.V. (Leuven, Belgium) debuted with a €27 million ($31.8 million) series A round from LSP, PMV, Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+. Aelin spun out of the...
23:59 , Dec 11, 2017 |  BC Extra  |  Financial News

VIB spinout Aelin raises €27M in series A

Aelin Therapeutics N.V. (Leuven, Belgium) debuted with a €27 million ($31.8 million) series A round from LSP, PMV, Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+. Aelin spun out of the Flanders Institute for...